This inventor holds 18 USPTO granted patents and 5 EPO patents. Top assignees: Daiichi Sankyo Company, Limited, Mitsubishi-Kagaku Foods Corporation, Takeshi Imanishi. Active years: 1991-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Nara-ken, JP (2001)
- Nara-shi, Nara JP (2000 - 2008)
- Suita, JP (2014)
- Nara, JP (1991 - 2015)
- Osaka, JP (2015)
Company Filing History:
4 out of 462 
3 out of 11 
3 out of 3 
Years Active: 1991-2015
Title: The Innovative Contributions of Takeshi Imanishi in Oligonucleotide Research
Introduction
Takeshi Imanishi, a prominent inventor based in Nara, Japan, has made significant strides in the field of biotechnology, particularly in the development of oligonucleotide therapies. With an impressive portfolio of 18 patents, he has established himself as a leading figure in advancing medical treatments aimed at dyslipidemia.
Latest Patents
Among Imanishi's latest innovations are two noteworthy patents: one for an oligonucleotide and therapeutic agent specifically designed for dyslipidemia. This invention focuses on providing an effective oligonucleotide that demonstrates excellent binding affinity to the PCSK9 gene, ensuring stability and safety. Moreover, this therapeutic agent is formulated with bioabsorbable materials, such as atelocollagen or peptide gel, enhancing its efficacy and usability. The second patent addresses a method for using oligonucleotide analogues for the prevention or treatment of diseases that are amenable to pharmacological intervention, emphasizing the potential of these compounds in medicinal applications.
Career Highlights
Imanishi has been integral to the research and development efforts in significant companies, notably Daiichi Sankyo Company, Limited. His work has led to advancements that bridge the gap between theoretical research and practical applications, particularly in pharmacology. His contributions in the field are recognized for merging scientific innovation with practical, therapeutic solutions.
Collaborations
Throughout his career, Takeshi Imanishi has collaborated with notable coworkers, including Satoshi Obika and Masakatsu Kaneko. These partnerships have facilitated the exchange of ideas and expertise, further driving the advancement of their collective research endeavors in oligonucleotide therapies.
Conclusion
Takeshi Imanishi's inventive spirit and dedication to the field of biotechnology have positioned him as a vital player in developing therapeutic agents for dyslipidemia. His ongoing innovations and patents reflect a commitment to enhancing healthcare outcomes through scientific research and collaboration, promising a brighter future in the treatment of genetic and metabolic disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile